- Study: Cough-cold manufacturers' voluntary label change on pediatric products reduced ER admissions
- Study: 2,000 IUs of vitamin E daily effective in slowing functional decline in AD patients
- PhRMA report lists 271 vaccines in development
- ROUNDTABLE: Pharmacy’s future in sync with technology
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
NOVATO, Calif. BioMarin Pharmaceutical on Monday announced its investigational treatment for a lysosomal storage disorder has received orphan-drug designation from the Food and Drug Administration.
The investigational drug BMN-701, designed to treat Pompe disease, has been submitted to the FDA for regulatory approval. Pompe disease is a progressive degenerative disease of the heart muscle, diaphragm and skeletal muscle.
"This [designation] emphasizes our mission of developing innovative, products for orphan diseases with an unmet medical need. We believe BMN-701 has the potential to possibly deliver more enzyme to lysosomes compared to traditional mannose-6-phosphate targeted approaches using the recently acquired GILT technology," said Jean-Jacques Bienaime, BioMarin CEO.